Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT02275416 | Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma | completed | Phase 1 / Phase 2 | 12 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03153085 | A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma | completed | Phase 2 | 28 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02301611 | Phase IIB TL + YCWP + DC in Melanoma | completed | Phase 2 | 187 | Elios Therapeutics, LLCINDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02392871 | Radiotherapy & Combi in Metastatic Melanoma(CombiRT) | completed | Phase 1 / Phase 2 | 10 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT03341143 | Fecal Microbiota Transplant (FMT) in Melanoma Patients | completed | Phase 2 | 20 | Zarour, Hassane, MDOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04091217 | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | completed | Phase 2 | 43 | Hoffmann-La RocheINDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03776136 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | completed | Phase 2 | 103 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 9, 2024 | clinicaltrials |
| NCT01740557 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02027935 | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03200847 | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 1 / Phase 2 | 26 | University of Colorado, DenverOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | completed | Phase 1 / Phase 2 | 24 | Lokon Pharma ABINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01256359 | Docetaxel With or Without AZD6244 in Melanoma(DOC-MEK) | completed | Phase 2 | 83 | University of OxfordOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT03455764 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03101254 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | completed | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT01894672 | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | completed | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)(Mel66) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02981303 | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | completed | Phase 2 | 64 | HiberCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02509598 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | completed | Phase 2 | 24 | Cardinal Health 414, LLCINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03484923 | Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma(PLATforM) | completed | Phase 2 | 196 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 18, 2024 | clinicaltrials |
| NCT02631447 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study(SECOMBIT) | completed | Phase 2 | 251 | Fondazione Melanoma OnlusOTHER | 10 | Jun 7, 2024 | clinicaltrials |
| NCT01119508 | Ipilimumab + Temozolomide in Metastatic Melanoma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02107755 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | completed | Phase 1 / Phase 2 | 217 | AmgenINDUSTRY | 3 | May 14, 2024 | clinicaltrials |
| NCT02970981 | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | completed | Phase 2 | 18 | NYU Langone HealthOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT03711188 | A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma | completed | Phase 2 | 16 | Immodulon Therapeutics LtdINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | completed | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02678741 | Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. | completed | Phase 1 / Phase 2 | 26 | Elios Therapeutics, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02159066 | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma(LOGIC-2) | completed | Phase 2 | 158 | PfizerINDUSTRY | 9 | Mar 5, 2024 | clinicaltrials |
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019448 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019890 | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 0 | Mar 4, 2024 | clinicaltrials |
| NCT00020475 | Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02126579 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists(MEL60) | completed | Phase 1 / Phase 2 | 50 | Craig L Slingluff, JrOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma(Mel-65) | completed | Phase 1 / Phase 2 | 33 | Craig L Slingluff, JrOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03052127 | Study in Subjects With Small Primary Choroidal Melanoma | completed | Phase 1 / Phase 2 | 57 | Aura BiosciencesINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT00866840 | Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT03850691 | Radiation and Combination Immunotherapy for Melanoma | completed | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03765229 | An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | completed | Phase 2 | 11 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT03123783 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 140 | Apexigen America, Inc.INDUSTRY | 2 | Dec 26, 2023 | clinicaltrials |
| NCT02101008 | Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy | completed | Phase 2 | 12 | University of UtahOTHER | 0 | Dec 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 1, 2025source: clinicaltrials